The addition of imatinib in prostate cancer had no impact on outcome, although there are strong pre-clinical results indicating an impact of imatinib on potentially clinical relevant PDGFR inhibition in prostate cancer [57]. Here, PDGFRB is linked to Familial prostate cancer.